Precipio Narrows Losses, Boosts Revenue Amid Going Concern Doubts

TL;DR

Precipio's revenue surge and shrinking losses are promising, but the lingering 'going concern' warning means this stock is still a high-risk bet.

AI Summary

Precipio, Inc. (PRPO) reported a significant increase in revenue for the three and nine months ended September 30, 2025, alongside a substantial reduction in net loss. Service revenue, net, grew to $6.164 million for the three months ended September 30, 2025, up from $4.599 million in the prior year, representing a 34% increase. For the nine months, service revenue reached $15.426 million, a 36% increase from $11.329 million in 2024. Product revenue also saw growth, reaching $721,000 for the three months and $1.999 million for the nine months. The net loss for the three months ended September 30, 2025, dramatically improved to $79,000, a 87% reduction from a $626,000 loss in the same period of 2024. Similarly, the nine-month net loss decreased by 77% to $889,000 from $3.925 million. The company's cash position improved significantly, with cash at the end of the period rising to $2.305 million as of September 30, 2025, from $1.389 million at December 31, 2024. This improvement was partly driven by $1.260 million in proceeds from warrant exercises during the nine months ended September 30, 2025, and a $789,000 Employee Retention Credit. Despite these positive financial trends, the company still carries an accumulated deficit of $103.3 million and management noted substantial doubt about its ability to continue as a going concern for the next twelve months.

Why It Matters

Precipio's significant revenue growth and reduced net loss are critical for investors, signaling potential operational improvements in the competitive cancer diagnostics market. The 36% increase in nine-month service revenue to $15.426 million demonstrates stronger market penetration for its diagnostic products and services, which could attract new customers and employees. However, the persistent 'going concern' doubt, despite a cash increase to $2.305 million, highlights ongoing financial instability and the need for sustained profitability or further capital raises, potentially impacting investor confidence and the company's ability to compete with larger diagnostic firms like ThermoFisher and McKesson.

Risk Assessment

Risk Level: high — The company explicitly states "substantial doubt about the Company's ability to continue as a going concern for the next twelve months" despite a net cash provided by operating activities of $0.3 million for the nine months ended September 30, 2025. This is further evidenced by an accumulated deficit of $103.3 million as of September 30, 2025, indicating a history of unprofitability and a precarious financial position.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in Precipio. While revenue growth is positive, the explicit 'going concern' warning and substantial accumulated deficit suggest significant financial risk. Monitor future filings for sustained profitability and successful capital raises before taking a position.

Financial Highlights

debt To Equity

0.54

revenue

$6.767M

operating Margin

N/A

total Assets

$21.153M

total Debt

$1.154M

net Income

-$79,000

eps

N/A

gross Margin

44.4%

cash Position

$2.305M

revenue Growth

+29.9%

Revenue Breakdown

Key Numbers

• $6.164M — Service revenue, net (Q3 2025) (Increased 34% from $4.599M in Q3 2024)
• $15.426M — Service revenue, net (9 months 2025) (Increased 36% from $11.329M in 9 months 2024)
• $79K — Net loss (Q3 2025) (Reduced 87% from $626K in Q3 2024)
• $889K — Net loss (9 months 2025) (Reduced 77% from $3.925M in 9 months 2024)
• $2.305M — Cash at end of period (Sep 30, 2025) (Increased from $1.389M at Dec 31, 2024)
• $1.260M — Proceeds from warrant exercises (9 months 2025) (Contributed to cash increase)
• $789K — Employee Retention Credit (9 months 2025) (Contributed to cash increase)
• $103.3M — Accumulated deficit (Sep 30, 2025) (Indicates historical losses)
• 1,752,007 — Common stock shares outstanding (Nov 11, 2025) (Total shares outstanding)
• $1.2M — Working capital (Sep 30, 2025) (Current assets minus current liabilities)

Key Players & Entities

• Precipio, Inc. (company) — registrant
• SEC (regulator) — filing authority
• ThermoFisher (company) — global healthcare distributor partner
• McKesson (company) — global healthcare distributor partner
• Medline (company) — global healthcare distributor partner
• Cardinal Health (company) — global healthcare distributor partner
• FASB (regulator) — accounting standards setter
• New Haven, Connecticut (location) — location of CLIA laboratory and R&D facilities
• Omaha, Nebraska (location) — location of R&D facilities and CLIA laboratory

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Management has substantial doubt about the company's ability to continue as a going concern for the next twelve months, despite recent improvements. The company still carries a significant accumulated deficit of $103.3 million.
• Accumulated Deficit [high — financial]: The company has an accumulated deficit of $103.3 million as of September 30, 2025. This indicates a history of net losses and raises concerns about long-term profitability and financial stability.
• Dependence on Key Services/Products [medium — operational]: While service revenue is growing, the company's reliance on specific service lines or products could pose a risk if demand shifts or competition intensifies. Specific details on product revenue drivers are limited.
• Cash Burn Rate [medium — financial]: Although cash increased to $2.305 million, the company's ability to sustain operations and growth without further financing remains a concern given the historical losses and ongoing operational costs.
• Employee Retention Credit Compliance [low — regulatory]: The company benefited from a $789,000 Employee Retention Credit. Ensuring compliance with all regulations related to such credits is crucial to avoid potential future liabilities or penalties.

Industry Context

Precipio operates in the diagnostic and healthcare technology sector, which is characterized by rapid innovation, stringent regulatory oversight, and increasing demand for efficient and accurate diagnostic solutions. The competitive landscape includes established players and emerging companies focused on specialized diagnostic platforms and services. Trends include the shift towards personalized medicine, the integration of AI in diagnostics, and the growing importance of point-of-care testing.

Regulatory Implications

The company must adhere to healthcare regulations, including those related to diagnostic testing and data privacy (e.g., HIPAA). The receipt of the Employee Retention Credit also implies compliance with specific IRS guidelines. Any missteps in regulatory compliance could lead to fines, reputational damage, and operational disruptions.

What Investors Should Do

1. Monitor cash burn and runway
2. Analyze drivers of service revenue growth
3. Evaluate path to profitability
4. Assess impact of financing activities

Key Dates

• 2025-09-30: End of Q3 2025 — Reported significant revenue growth and reduced net loss, with cash position improving to $2.305M.
• 2025-09-30: Nine months ended September 30, 2025 — Service revenue grew 36% to $15.426M, net loss reduced significantly, and $1.260M received from warrant exercises.
• 2024-12-31: End of Fiscal Year 2024 — Cash position was $1.389M, serving as a baseline for the current period's improvement.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. It represents a negative balance in retained earnings. (Indicates Precipio's history of losses, standing at $103.3 million as of September 30, 2025, which is a key factor in the going concern assessment.)

Going concern

An accounting assumption that a business will continue to operate for the foreseeable future, typically at least 12 months. If there is substantial doubt about this, it must be disclosed. (Management has stated substantial doubt about Precipio's ability to continue as a going concern, highlighting significant financial risks.)

Warrant exercises

The act of a holder of a stock warrant using their right to purchase shares of a company's stock at a specified price. (Precipio received $1.260 million from warrant exercises in the first nine months of 2025, contributing to its improved cash position.)

Employee Retention Credit (ERC)

A refundable tax credit designed to encourage employers to keep employees on payroll during the COVID-19 pandemic. (Precipio received $789,000 from the ERC, which positively impacted its cash flow and liquidity.)

Service revenue, net

Revenue generated from providing services, after accounting for any contractual allowances, adjustments, and provisions for credit losses. (This is Precipio's primary revenue stream, showing strong growth of 34% year-over-year for Q3 2025.)

Net sales

The total revenue of a company after deducting returns, allowances, and discounts. (Represents the top-line revenue figure after adjustments, which increased by 29.9% for Q3 2025.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Precipio has demonstrated significant top-line growth, with service revenue increasing by 34% in Q3 and 36% year-to-date. This revenue expansion has translated into a substantial reduction in net losses, with Q3 net loss shrinking by 87%. The company's cash position has also improved considerably, partly due to warrant exercises and an Employee Retention Credit. However, the persistent accumulated deficit and the explicit 'going concern' warning remain critical concerns, indicating ongoing financial fragility despite operational improvements.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value per share PRPO The Nasdaq

Filing Documents

• prpo-20250930x10q.htm (10-Q) — 1768KB
• prpo-20250930xex31d1.htm (EX-31.1) — 13KB
• prpo-20250930xex31d2.htm (EX-31.2) — 14KB
• prpo-20250930xex32d1.htm (EX-32.1) — 6KB
• prpo-20250930xex32d2.htm (EX-32.2) — 6KB
• 0001104659-25-112601.txt ( ) — 8371KB
• prpo-20250930.xsd (EX-101.SCH) — 54KB
• prpo-20250930_cal.xml (EX-101.CAL) — 72KB
• prpo-20250930_def.xml (EX-101.DEF) — 223KB
• prpo-20250930_lab.xml (EX-101.LAB) — 451KB
• prpo-20250930_pre.xml (EX-101.PRE) — 371KB
• prpo-20250930x10q_htm.xml (XML) — 1662KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 33 PART II. Other Information 34 Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2 . Unregistered Sales of Equity Securities and Use of Proceeds 36 Item 3 . Defaults Upon Senior Securities 36 Item 4 . Mine Safety Disclosures 36 Item 5 . Other Information 36 Item 6. Exhibits 37

Signatures

Signatures 38 2 Table of Contents PART 1. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements PRECIPIO, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in thousands, except share data) (unaudited) September 30, 2025 December 31, 2024 ASSETS CURRENT ASSETS: Cash $ 2,305 $ 1,389 Accounts receivable (net of allowance for credit losses of $ 1,050 and $ 995 , respectively) 1,957 799 Inventories 788 724 Other current assets 618 539 Total current assets 5,668 3,451 PROPERTY AND EQUIPMENT, NET 771 719 OTHER ASSETS: Finance lease right-of-use assets, net 1,059 517 Operating lease right-of-use assets, net 2,431 395 Intangibles, net 11,157 11,869 Other assets 67 45 Total assets $ 21,153 $ 16,996 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Current maturities of long-term debt, less debt issuance costs $ 30 $ 297 Current maturities of finance lease liabilities 215 124 Current maturities of operating lease liabilities 366 201 Accounts payable 1,138 618 Accrued expenses 2,428 2,799 Deferred revenue 276 232 Total current liabilities 4,453 4,271 LONG TERM LIABILITIES: Long-term debt, less current maturities and debt issuance costs 55 77 Finance lease liabilities, less current maturities 799 348 Operating lease liabilities, less current maturities 2,097 206 Total liabilities 7,404 4,902 COMMITMENTS AND CONTINGENCIES (Note 5) STOCKHOLDERS' EQUITY: Preferred stock - $ 0.01 par value, 15,000,000 shares authorized at September 30, 2025 and December 31, 2024, 47 shares issued and outstanding at September 30, 2025 and December 31, 2024, liquidation preference of $ 105 at September 30, 2025 — — Common stock, $ 0.01 par value, 150,000,000 shares authorized at September 30, 2025 and December 31, 2024, 1,745,887 and 1,493,639 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 17 15 Additional paid-in capital 117,06

View Full Filing

View this 10-Q filing on SEC EDGAR